newsfilter
← Latest News
GlobeNewswire·

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

  • Seres Therapeutics (NASDAQ: MCRB) will host a conference call & live webcast on November 5, 2025 at 8:30 a.m. ET to discuss Q3 2025 financial results & business updates.
  • Access details include dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 8471287, or visiting www.serestherapeutics.com.
  • A webcast replay will be archived on the company website for approximately 21 days following the event.
  • VOWST, the first FDA-approved orally administered microbiome therapeutic developed by Seres, was sold to Nestlé Health Science in September 2024.
  • SER-155 holds Breakthrough Therapy & Fast Track designations for reducing bloodstream infections & the risk of infection & graft-versus-host disease in adults undergoing allo-HSCT.
  • Phase 1b clinical studies demonstrated SER-155 significantly reduced bloodstream infections & related complications compared to placebo in allo-HSCT patients.
  • SER-155 & other pipeline programs are cultivated from standard clonal cell banks, differing from the donor-sourced production process used for VOWST.
  • Future evaluation plans for SER-155 & other candidates include autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, ICU patients, & long-term acute care facility patients.